EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische Studie

PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer

Jennifer J Knox iD, Grainne O'Kane iD, Daniel King, Daniel Laheru iD, Amber N Habowski iD, Kenneth Yu iD, Kimberly Perez iD, Andrew J Aguirre iD, Zachary Coyne, Harry Harvey iD, Ronan A McLaughlin, Raymond W Jang iD und 24 weitere

Journal of Clinical Oncology · 2025-11 · 43 (31) · 3355-3368

DOI: 10.1200/jco-25-00436 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025-11. Verfasst von Jennifer J Knox und 35 weiteren Autor:innen. Beteiligte Einrichtung: McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To assess modified folinic acid/leucovorin, fluorouracil, irinotecan, oxaliplatin (FOLFIRINOX [mFFX]) versus gemcitabine/nab-paclitaxel (GnP) in de novo metastatic pancreatic ductal adenocarcinoma (PDAC) and explore predictive biomarkers. PATIENTS AND METHODS Patients were randomly assigned 1:1 to mFFX or GnP with exclusion of germline pathogenic variants in BRCA1/2 or PALB2 . The primary end point was progression-free survival (PFS) between arms with 0.3 significance. The per-protocol (PP) population included patients who received one dose of chemotherapy. Pretreatment biopsies underwent whole-genome/transcriptome sequencing and patient-derived organoid (PDO) development, providing correlate recommendations at a molecular tumor board and outcomes assessed according to RNA signatures (basal-like v classical). RESULTS Of 160 patients randomly assigned (80 mFFX, 80 GnP), 140 patients were in the PP population (71 mFFX, 69 GnP), with median follow-up of 8.3 months. The median PFS was 4.0 months for mFFX versus 5.3 months for GnP (hazard ratio [HR], 1.37 [95% CI, 0.97 to 1.92]; P = .069) in intention-to-treat. Median overall survival (OS) was 8.5 months with mFFX and 9.7 months with GnP (HR, 1.57 [95% CI, 1.08 to 2.28]; P = .017). Genomic data were generated in 94%, transcriptomes in 74%, and PDOs in 50%. The median PFS for those with basal-like was 3.0 (mFFX) and 5.5 (GnP) months ( P = .17), and classical PDAC was 6.3 (mFFX) versus 5.4 (GnP) months ( P = .36). The median OS in basal-like was 7.5 (mFFX) and 8.9 (GnP) months ( P = .75) versus in classical OS was 9.7 (mFFX) and 13.9 (GnP) months ( P = .047). Overall, 75 (54%) of patients received second-line treatment, 33/75 (44%) correlate-guided. The median time on second-line treatment was only 2.1 months with a median OS of 5.4 months for a correlate-guided choice versus 4.4 months on a standard chemotherapy approach ( P = .45). CONCLUSION In the phase II Pancreatic Adenocarcinoma Signature Stratification for Treatment-01 (PASS-01) trial population, PFS was similar between GnP and mFFX; however, OS and safety trends favored GnP. The second-line setting appears inadequate to offer precision choices, given the short survival observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalHumansFemaleLeucovorinPaclitaxelMaleGemcitabineIrinotecanDeoxycytidineMiddle AgedOxaliplatinAgedFluorouracilAlbuminsAdultBiomarkers, TumorProgression-Free Survival

Substanzen

LeucovorinPaclitaxelGemcitabineIrinotecan130-nm albumin-bound paclitaxelDeoxycytidineOxaliplatinFluorouracilfolfirinoxAlbumins

Autor:innen und Institutionen

  • McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Northwell Health Cancer Institute, Lake Success, NY.
  • Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine, Baltimore, MD.
  • Lustgarten Foundation Pancreatic Cancer Research Laboratory, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.
  • Dana Farber Cancer Institute and Harvard Medical School, Boston, MA.

ORCID-Profile: Jennifer J Knox, Grainne O'Kane, Daniel Laheru, Amber N Habowski, Kenneth Yu, Kimberly Perez, Andrew J Aguirre, Harry Harvey, Raymond W Jang, Robert C Grant, Craig E Devoe, Harshabad Singh, Michael J Pishvaian, Fieke E M Froeling, Eileen M O'Reilly, Erica S Tsang, Brian M Wolpin, Julie M Wilson, Trevor J Pugh, Xiang Y Ye, Steven Gallinger

Förderung

  • NCI NIH HHS

Zitieren

APA

Knox, J. J., O'Kane, G., King, D., Laheru, D., Habowski, A. N., Yu, K., Perez, K., Aguirre, A. J., Coyne, Z., Harvey, H., McLaughlin, R. A., Jang, R. W., Grant, R. C., Elimova, E. C., Renouf, D. J., Fischer, S., Duan, K., Ramotar, S., Jang, G. H., …, & Jaffee, E. M. (2025). PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 43(31), 3355-3368. https://doi.org/10.1200/jco-25-00436

Vancouver

Knox JJ, O'Kane G, King D, Laheru D, Habowski AN, Yu K, et al. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. Journal of Clinical Oncology. 2025;43(31):3355-3368. doi:10.1200/jco-25-00436

BibTeX
@article{Knox2025,
  author = {Knox, Jennifer J and O'Kane, Grainne and King, Daniel and Laheru, Daniel and Habowski, Amber N and Yu, Kenneth and Perez, Kimberly and Aguirre, Andrew J and Coyne, Zachary and Harvey, Harry and McLaughlin, Ronan A and Jang, Raymond W and Grant, Robert C and Elimova, Elena C and Renouf, Daniel J and Fischer, Sandra and Duan, Kai and Ramotar, Stephanie and Jang, Gun Ho and Zhang, Amy and Devoe, Craig E and Singh, Harshabad and Pishvaian, Michael J and Froeling, Fieke E M and Saif, Muhammad W and O'Reilly, Eileen M and Tsang, Erica S and Wolpin, Brian M and Wilson, Julie M and Dodd, Anna and Pugh, Trevor J and Ye, Xiang Y and Gallinger, Steven and Tuveson, David A and Notta, Faiyaz and Jaffee, Elizabeth M},
  title = {PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {31},
  pages = {3355--3368},
  doi = {10.1200/jco-25-00436}
}
Kostenlos starten →